RE:RE:RE:RE:NewsThere are still 8 in there Pandora.Three of them have already had their second treatment - and very possibly under-treated for a second time - and five (all of whom have already registered a positive response notwithstanding their first under-treatment) are scheduled to receive their second treatment at the correct dosages of compound and light.
Had thought such issues resolved with that delay in Phase IB. When they have the twin protections of the steep gradient under green light and the fact that the compound is simply not taken up by healthy urothlelium it is disappointing to have under-treatment by such large margins.
Anyway this is experimental stuff and provided they now have the answers the Covid/FDA delays that we have all been moaning about may actually have proven a blessing.
As for the stock it`s not for widows and orphans but there are some wilting violets here - folks seem to be bailing out on a complete misunderstanding of what is being reported just as they did in the middle of Phase IB. They may rue this `ere long given what is happening with TLD-1433/Rutherrin elsewhere.